newsfilter
← Latest News
GlobeNewswire·

Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder on track for joint topline readout in the second quarter of 2026 Progressing NMRA-511 in Alzheimer's disease agitation and NMRA-898 in